Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX

Hongxia Niu, Lina Hu, Qing Li, Zejiao Da, Bingxiang Wang, Kefeng Tang, Qi Xin, Hongjuan Yu, Ying Zhang, Yong Wang, Xingming Ma, Bingdong Zhu

Research output: Contribution to journalArticle

Abstract

To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4-HspX (MH for short) without affinity tag with potential advantage for clinical use. The human T-cell responses to MH were evaluated for its immunogenicity. Furthermore, MH was emulsified in an adjuvant composed of N,N'-dimethyl-N,N'-dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. The results showed that the fusion protein MH without affinity tag was stably produced in Escherichia coli and was successfully purified by chromatography. MH was strongly recognized by human T cells from TB patients and persons latently infected with M. tuberculosis. In conclusion, MH in adjuvant DDA-TDM generated strong antigen-specific humoral and cell-mediated immunity, and had the capability to enhance BCG-primed immunity and the protective efficacy against M. tuberculosis in mice. These findings suggest that MH in DDA-TDM have the potential to be a good multistage tuberculosis vaccine candidate.

Original languageEnglish (US)
Pages (from-to)9451-9458
Number of pages8
JournalVaccine
Volume29
Issue number51
DOIs
StatePublished - Nov 28 2011

Fingerprint

Tuberculosis Vaccines
Subunit Vaccines
subunit vaccines
Mycobacterium tuberculosis
Trehalose
trehalose
bromides
Bromides
immune response
Bacillus
adjuvants
Immunity
Cord Factors
T-lymphocytes
immunity
Vaccine Potency
vaccines
antigens
T-Lymphocytes
Antigens

Keywords

  • HspX
  • Mtb10.4
  • Multi-stage vaccine
  • Mycobacterium tuberculosis
  • Subunit vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. / Niu, Hongxia; Hu, Lina; Li, Qing; Da, Zejiao; Wang, Bingxiang; Tang, Kefeng; Xin, Qi; Yu, Hongjuan; Zhang, Ying; Wang, Yong; Ma, Xingming; Zhu, Bingdong.

In: Vaccine, Vol. 29, No. 51, 28.11.2011, p. 9451-9458.

Research output: Contribution to journalArticle

Niu, H, Hu, L, Li, Q, Da, Z, Wang, B, Tang, K, Xin, Q, Yu, H, Zhang, Y, Wang, Y, Ma, X & Zhu, B 2011, 'Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX', Vaccine, vol. 29, no. 51, pp. 9451-9458. https://doi.org/10.1016/j.vaccine.2011.10.032
Niu, Hongxia ; Hu, Lina ; Li, Qing ; Da, Zejiao ; Wang, Bingxiang ; Tang, Kefeng ; Xin, Qi ; Yu, Hongjuan ; Zhang, Ying ; Wang, Yong ; Ma, Xingming ; Zhu, Bingdong. / Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. In: Vaccine. 2011 ; Vol. 29, No. 51. pp. 9451-9458.
@article{346471caa1384463810dac8ebdac94c9,
title = "Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX",
abstract = "To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4-HspX (MH for short) without affinity tag with potential advantage for clinical use. The human T-cell responses to MH were evaluated for its immunogenicity. Furthermore, MH was emulsified in an adjuvant composed of N,N'-dimethyl-N,N'-dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. The results showed that the fusion protein MH without affinity tag was stably produced in Escherichia coli and was successfully purified by chromatography. MH was strongly recognized by human T cells from TB patients and persons latently infected with M. tuberculosis. In conclusion, MH in adjuvant DDA-TDM generated strong antigen-specific humoral and cell-mediated immunity, and had the capability to enhance BCG-primed immunity and the protective efficacy against M. tuberculosis in mice. These findings suggest that MH in DDA-TDM have the potential to be a good multistage tuberculosis vaccine candidate.",
keywords = "HspX, Mtb10.4, Multi-stage vaccine, Mycobacterium tuberculosis, Subunit vaccine",
author = "Hongxia Niu and Lina Hu and Qing Li and Zejiao Da and Bingxiang Wang and Kefeng Tang and Qi Xin and Hongjuan Yu and Ying Zhang and Yong Wang and Xingming Ma and Bingdong Zhu",
year = "2011",
month = "11",
day = "28",
doi = "10.1016/j.vaccine.2011.10.032",
language = "English (US)",
volume = "29",
pages = "9451--9458",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "51",

}

TY - JOUR

T1 - Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX

AU - Niu, Hongxia

AU - Hu, Lina

AU - Li, Qing

AU - Da, Zejiao

AU - Wang, Bingxiang

AU - Tang, Kefeng

AU - Xin, Qi

AU - Yu, Hongjuan

AU - Zhang, Ying

AU - Wang, Yong

AU - Ma, Xingming

AU - Zhu, Bingdong

PY - 2011/11/28

Y1 - 2011/11/28

N2 - To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4-HspX (MH for short) without affinity tag with potential advantage for clinical use. The human T-cell responses to MH were evaluated for its immunogenicity. Furthermore, MH was emulsified in an adjuvant composed of N,N'-dimethyl-N,N'-dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. The results showed that the fusion protein MH without affinity tag was stably produced in Escherichia coli and was successfully purified by chromatography. MH was strongly recognized by human T cells from TB patients and persons latently infected with M. tuberculosis. In conclusion, MH in adjuvant DDA-TDM generated strong antigen-specific humoral and cell-mediated immunity, and had the capability to enhance BCG-primed immunity and the protective efficacy against M. tuberculosis in mice. These findings suggest that MH in DDA-TDM have the potential to be a good multistage tuberculosis vaccine candidate.

AB - To search for more effective vaccines to enhance the immunogenicity and protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin (BCG) and to control or even eradicate Mycobacterium tuberculosis (M. tuberculosis) in all stages of infection including the persister bacteria, antigens of Mtb10.4 (Rv0288) expressed in replicating bacilli and HspX (also called Acr, Hsp16.3, Rv2031c) highly expressed in dormant bacilli were fused together to construct a multistage fusion protein Mtb10.4-HspX (MH for short) without affinity tag with potential advantage for clinical use. The human T-cell responses to MH were evaluated for its immunogenicity. Furthermore, MH was emulsified in an adjuvant composed of N,N'-dimethyl-N,N'-dioctadecylammonium bromide (DDA) and mycobacterial cord factor trehalose-6,6-dimycolate (TDM) to construct subunit vaccine, whose immunogenicity and potency to boost BCG primed immunity against M. tuberculosis infection were evaluated in mice. The results showed that the fusion protein MH without affinity tag was stably produced in Escherichia coli and was successfully purified by chromatography. MH was strongly recognized by human T cells from TB patients and persons latently infected with M. tuberculosis. In conclusion, MH in adjuvant DDA-TDM generated strong antigen-specific humoral and cell-mediated immunity, and had the capability to enhance BCG-primed immunity and the protective efficacy against M. tuberculosis in mice. These findings suggest that MH in DDA-TDM have the potential to be a good multistage tuberculosis vaccine candidate.

KW - HspX

KW - Mtb10.4

KW - Multi-stage vaccine

KW - Mycobacterium tuberculosis

KW - Subunit vaccine

UR - http://www.scopus.com/inward/record.url?scp=81955164734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81955164734&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.10.032

DO - 10.1016/j.vaccine.2011.10.032

M3 - Article

C2 - 22024175

AN - SCOPUS:81955164734

VL - 29

SP - 9451

EP - 9458

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 51

ER -